trial

Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

NCTId NCT05473741
as of 2026-07-01
at a glance
Phase — · Completed
Enrollment 51 (actual)
Primary completion 2025-10-27
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Status
Completed
Enrollment
51 (actual)
Study type
Observational
Allocation
Model
Masking
Start
2023-01-11
Primary completion
2025-10-27
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Sponsors

Investigators

1
Robert B Zipursky, MDPrincipal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
51
Phase
NA
Primary Completion Date
2025-10-27
Status
COMPLETED